Bibliography
- Lazarou J , PomeranzBH, CoreyPN: Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.JAMA279(15) , 1200–1205 (1998).
- Wysowski D , SwartzL: Adverse drug event surveillance and drug withdrawals in the United States, 1969–2002.Arch. Intern. Med.165 , 1363–1369 (2005).
- Pichler WJ : Delayed drug hypersensitivity reactions.Ann. Intern. Med.139(8) , 683–693 (2003).
- Matzinger P : Tolerance, danger, and the extended family.Annu. Rev. Immunol.12 , 991–1045 (1994).
- Torres MJ , MayorgaC, BlancaM: Nonimmediate allergic reactions induced by drugs: pathogenesis and diagnostic tests.J. Investig. Allergol. Clin. Immunol.19(2) , 80–90 (2009).
- Dedeoglu F : Drug-induced autoimmunity.Curr. Opin. Rheumatol.21(5) , 547–551 (2009).
- Hetherington S , HughesA, MostellerM et al.: Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.Lancet359 , 1121–1122 (2002).
- Mallal S , NolanD, WittC et al.: Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.Lancet359(9308) , 727–732 (2002).
- Mallal S , PhillipsE, CarosiG et al.: HLA-B*5701 screening for hypersensitivity to abacavir.N. Engl. J. Med.358 , 568–579 (2008).
- Higgs J , GambhirN, RamsdenSC, PoultonK, NewmanWG: Pharmacogenetic testing in the United Kingdom genetics and immunogenetics laboratories.Genet. Test Mol. Biomarkers14(1) , 121–125 (2009).
- Watson ME , PatelLG, HaB, WannamakerP, CuffeR, ShaeferM: A study of HIV provider attitudes toward HLA-B 5701 testing in the United States.AIDS Patient Care STDS23(11) , 957–963 (2009).
- Young B , SquiresK, PatelP et al.: First large, multicenter, open-label study utilizing HLA-B*5701 screening for abacavir hypersensitivity in North America.AIDS22(13) , 1673–1675 (2008).
- Chung W , HungS, HongH et al.: Medical genetics: a marker for Stevens–Johnson syndrome.Nature428 , 486 (2004).
- Locharernkul C , LoplumlertJ, LimotaiC et al.: Carbamazepine and phenytoin induced Stevens–Johnson syndrome is associated with HLA-B*1502 allele in Thai population.Epilepsia49(12) , 2087–2091 (2008).
- Holdsworth R , HurleyCK, MarshSG et al.: The HLA dictionary 2008: a summary of HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens.Tissue Antigens73(2) , 95–170 (2009).
- Horton R , WilmingL, RandV et al.: Gene map of the extended major histocompatibility complex.Nat. Rev. Genet.5 , 889–899 (2004).
- Nelson M , Bacanu S-A, Mosteller M et al.: Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions. Pharmacogenomics J.9(1) , 23–33 (2009).
- Daly A , DonaldsonP, BhatnagarP et al.: HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin.Nat. Genet.41 , 816–819 (2009).
- Becquemont L : Pharmacogenomics of adverse drug reactions: practical applications and perspectives.Pharmacogenomics10(6) , 961–969 (2009).
- Hughes DA , VilarFJ, WardCC, AlfirevicA, ParkBK, PirmohamedM: Cost–effectiveness analysis of HLA-B*5701 genotyping in preventing abacavir hypersensitivity.Pharmacogenetics14(6) , 335–342 (2004).
- Lonjou C , ThomasL, BorotN et al.: A marker for Stevens–Johnson syndrome: ethnicity matters.Pharmacogenomics J.6(4) , 265–268 (2006).
- Hung SI , ChungWH, JeeSH et al.: Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.Pharmacogenet. Genomics16(4) , 297–306 (2006).
- Hung S , ChungW, LiouL et al.: HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol.Proc. Natl Acad. Sci. USA102(11) , 4134–4139 (2005).
- Donaldson P , BhatnagarP, GrahamJ et al.: Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor.Hepatology48(Suppl. 4) , A396–A397 (2008).
- Martin A , NolanD, JamesI et al.: Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts.AIDS19 , 97–99 (2005).
- Littera R , CarcassiC, MasalaA et al.: HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients.AIDS20 , 1624–1626 (2006).
- Kindmark A , JawaidA, HarbronC et al.: Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis.Pharmacogenomics J.8 , 186–195 (2008).
- Gueant-Rodriguez RM , GueantJL, ViolaM, TramoyD, GaetaF, RomanoA: Association of tumor necrosis factor-α-308G>A polymorphism with ige-mediated allergy to betalactams in an Italian population.Pharmacogenomics J.8(2) , 162–168 (2008).
- Romano A , De Santis A, Romito A et al.: Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes. Ann. Allergy Asthma Immunol.80(5) , 433–437 (1998).
- O‘Donohue J , OienKA, DonaldsonP et al.: Co-amoxiclav jaundice: clinical and histological features and HLA class II association.Gut47(5) , 717–720 (2000).
- Dettling M , CascorbiI, Opgen-RheinC, SchaubR: Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens.Pharmacogenomics J.7(5) , 325–332 (2007).
- Lonjou C , BorotN, SekulaP et al.: A European study of HLA-B in Stevens–Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs.Pharmacogenet. Genomics18(2) , 99–107 (2008).
- Kim SH , ChoiJH, LeeKW et al.: The human leucocyte antigen-DRB1*1302-DQB1*0609-DPB1*0201 haplotype may be a strong genetic marker for aspirin-induced urticaria.Clin. Exp. Allergy35(3) , 339–344 (2005).